Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial

The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome.

开始日期2015-02-01

申办/合作机构

Technische Universität München

NCT02374567 / Terminated临床3期IIT

Pharmacovigilance in Gerontopsychiatric Patients

The purpose of this multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment.
The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises.
To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites.
At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed.
Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system.
In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually.
2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

开始日期2015-01-01

申办/合作机构

Hannover Medical School

NCT01498770 / CompletedN/A

An Observational Drug Utilization Study of SYCREST^® (Asenapine) in the United Kingdom

This study is designed to describe asenapine prescribing patterns in the United Kingdom (UK) during the post-approval period under conditions of usual practice. The use of asenapine in Bipolar Disorder and other indications will be described. To provide epidemiological and clinical perspective, use of aripiprazole and other comparator drugs will be described.

开始日期2013-04-01

申办/合作机构

Organon & Co.

100 项与舍吲哚相关的临床结果

登录后查看更多信息

100 项与舍吲哚相关的转化医学

登录后查看更多信息

100 项与舍吲哚相关的专利（医药）

登录后查看更多信息

546

项与舍吲哚相关的文献（医药）

2024-03-01·Journal of applied toxicology : JAT

Inhibition of voltage‐dependent K⁺ channels in rabbit coronary arterial smooth muscle cells by the atypical antipsychotic agent sertindole

Article

作者: Park, Minju ; Mun, Seo-Yeong ; Na, Sunghun ; Lee, Se Jin ; Park, Won Sun ; Kim, Hye Ryung ; Park, Hongzoo ; Zhuang, Wenwen ; Jeong, Junsu

Abstract:

The regulation of membrane potential and the contractility of vascular smooth muscle cells (VSMCs) by voltage‐dependent K+ (Kv) potassium channels are well‐established. In this study, native VSMCs from rabbit coronary arteries were used to investigate the inhibitory effect of sertindole, an atypical antipsychotic agent, on Kv channels. Sertindole induced dose‐dependent inhibition of Kv channels, with an IC50 of 3.13 ± 0.72 μM. Although sertindole did not cause a change in the steady‐state activation curve, it did lead to a negative shift in the steady‐state inactivation curve. The application of 1‐ or 2‐Hz train pulses failed to alter the sertindole‐induced inhibition of Kv channels, suggesting use‐independent effects of the drug. The inhibitory response to sertindole was significantly diminished by pretreatment with a Kv1.5 inhibitor but not by Kv2.1 and Kv7 subtype inhibitors. These findings demonstrate the sertindole dose‐dependent and use‐independent inhibition of vascular Kv channels (mainly the Kv1.5 subtype) through a mechanism that involves altering steady‐state inactivation curves. Therefore, the use of sertindole as an antipsychotic drug may have adverse effects on the cardiovascular system.

2023-11-01·Schizophrenia research

The cellular mechanism of antipsychotic-induced myocarditis: A systematic review

Review

作者: Bousman, Chad A ; Vaziri, Nazanin ; Greenway, Steven C ; Marques, Diogo

Antipsychotic drug-induced myocarditis is a serious and potentially fatal adverse drug reaction characterized by inflammation of the heart muscle (myocardium) that typically develops within the first month after commencing an antipsychotic drug. Although the precise mechanism of this severe adverse drug reaction is unknown, multiple theories have been proposed with varying levels of support from cellular or animal studies. We conducted a systematic review, in accordance with PRISMA guidelines, of published preclinical and clinical studies investigating the cellular mechanism by which antipsychotic drugs induce myocarditis. A literature search including all studies available before December 10, 2022, yielded 15 studies that met our inclusion criteria. Antipsychotics examined in the included studies included clozapine (n = 13), ziprasidone (n = 1), amisulpride (n = 1), haloperidol (n = 1), levomepromazine (n = 1), olanzapine (n = 1), and sertindole (n = 1). The evidence suggests several overlapping mechanistic cascades involving: (1) increased levels of catecholamines, (2) increased proinflammatory cytokines, (3) increased reactive oxygen species (ROS), (4) reduced antioxidant levels and activity, and (5) mitochondrial damage. Notable limitations such as, a focus on clozapine, sample heterogeneity, and use of supratherapeutic doses will need to be addressed in future studies. Discovery of the mechanism by which antipsychotic drugs induce myocarditis will allow the development of clinically-useful biomarkers to identify those patients at increased risk prior to drug exposure. The development or repurposing of therapeutics to prevent or treat drug-induced myocarditis will also be possible and this will enable increased and safe use of antipsychotics for those patients in need.

2023-10-11·Molecules (Basel, Switzerland)

Naphthaleneoxypropargyl-Containing Piperazine as a Regulator of Effector Immune Cell Populations upon an Aseptic Inflammation.

Article

作者: Balapanova, Anar Kh ; Balabekova, Marina K ; Dembitsky, Valery M ; Sycheva, Yelena S ; Seilkhanov, Tulegen M ; Zharkynbek, Tolganay Y ; Tokusheva, Aliya N ; Kairanbayeva, Gulgul K ; Yu, Valentina K ; Tassibekov, Khaidar S

This study investigated the effects of aseptic inflammation and heavy metal exposure on immune responses, as well as the potential immunomodulatory properties of the newly synthesized 1-[1-(2,5-dimethoxyphenyl)-4-(naphthalene-1-yloxy)but-2-ynyl]-4-methylpiperazine complexed with β-cyclodextrin (β-CD). Aseptic inflammation was induced by a subcutaneous injection of turpentine in rats, while heavy metal exposure was achieved through a daily administration of cadmium chloride and lead acetate. The levels of immune cell populations, including cytotoxic T lymphocytes (CTL), monocytes, and granulocytes, were assessed in the spleen. The results showed that aseptic inflammation led to decreased levels of CTL, monocytes, and granulocytes on the 14th day, indicating an inflammatory response accompanied by a migration of effector cells to the inflamed tissues. The exposure to cadmium chloride and lead acetate resulted in systemic immunotoxic effects, with reduced levels of B cells, CD4⁺ Th cells, monocytes, and granulocytes in the spleen. Notably, piperazine complexed with β-CD (the complex) exhibited significant stimulatory effects on CD4⁺, CD8⁺, and myeloid cell populations during aseptic inflammation, even in the presence of heavy metal exposure. These findings suggest the potential immunomodulatory properties of the complex in the context of aseptic inflammation and heavy metal exposure.

项与舍吲哚相关的新闻（医药）

2024-03-05

·精准药物

含吲哚药物结构与靶点，药理与SAR 研究归纳

吲哚是一种芳香杂环分子，具有一个苯环和一个含氮吡咯环组成的双环结构。吲哚中的氮原子提供一对孤对电子，形成共轭体系，从而稳定了吲哚结构。这对孤电子使吲哚化合物呈现弱碱性(pKa=16.2和pK,=17.6)。由于吡咯环的电子密度相对较高以及氮原子的共轭效应，吲哚可以在其吡咯环的3位发生亲电取代反应(图la)。图 1 (a) 全球有超过70种含有吲哚的合成药物在市场上销售，并被证明具有良好的医疗效果(图1b)。用于治疗的疾病包括糖尿病、癌症、白血病、丙型肝炎、心理障碍和其他临床问题。自2015年起，美国(FDA)专门批准了14种含吲哚药物，其中3种是在2021年批准的(图2)。二氢麦角胺(DHE,1)的化学结构中含有吲哚支架，对头颅血管平滑肌中的5-HT1b受体具有激动活性，治疗偏头痛。昂丹司琼(2)是一种血清素5-HT3受体拮抗剂，用于预防癌症治疗期间和手术后的恶心和呕吐(图3a)。图 3 (a) 双氢麦角胺（1）和昂丹司琼（2）的结构。(b) 双氢麦角胺(1)与其靶点（左）和昂丹司琼(2)与其靶点（右）的关键靶点相互作用。替加色罗(3)在临床相关水平上被认为是5-HT(4)受体的激动剂和5-HT(2B)受体的拮抗剂，其作用之一是使受损的胃肠道运动恢复正常。多拉司琼(4)用于中度致吐的癌症化疗以及术后恶心和呕吐的治疗(图5)。它是一种高效、选择性的血清素5-HT3受体拮抗剂。 Tropisetron（5）可抑制5HT3受体上血清素的活性，从而抑制放疗和化疗引起的呕吐。 Vilazodone(6)是5HT-1A受体的部分激动剂，专门抑制中枢神经系统对血清素的再摄取。在治疗偏头痛急性发作方面，三苯氧胺药物(5-羟色胺受体激动剂)比其他药物更有效、更耐受。这类药物具有起效快、用药时间长、不良反应少等优点。Sumatriptan(7),zolmitriptan(8),naratriptan(9), rizatriptan(10), almotriptan (11), frovatriptan (12), eletriptan (13), 和 oxitriptan (14) 是国外已商业化的曲坦类药物的代表。(图7)。环氧化酶(COX)被称为前列腺素G/H合成酶，而吲哚美辛是一种非特异性的可逆性环氧化酶抑制剂。吲哚美辛(18)属于吲哚-3-乙酸类，其官能团包括对氯苯甲酰基、甲基和甲氧基。它是一种非甾体抗炎药(NSAID), 具有消炎、镇痛和解热的特点(图11a)。 Acemetacin(19)是另一种强效非甾体抗炎药物，由吲哚-3-乙酸衍生而来(图12)。它主要通过酯分解代谢为吲哚美辛。 Etodolac(20)是一种非甾体抗炎药，具有消炎、镇痛和解热作用(图13a)。以前被认为是一种非选择性COX抑制剂，但现在被认为对COX-2的选择性是COX-1的5-50倍。 Carprofen(21)是兽医用作缓解老年犬关节炎症状的辅助疗法的一种非甾体抗炎药，人们认为卡洛芬(21)的作用机制是抑制环氧化酶的活性。帕金森病的药物 Cabergoline(22)是一种长效多巴胺受体激动剂，与D2受体有很强的亲和力，用于治疗高催乳素血症和帕金森综合症(图14a)。 Lisuride(23)可能是某些血清素受体的激动剂,也可能是多巴胺D1受体的拮抗剂。可降低催乳素水平，适量服用可阻止偏头痛，从药理上讲，(23)是还是一种帕金森氏症药物。治疗子宫脱垂的药物甲基麦角新碱(26)是一种麦角生物碱，临床上用于预防和治疗产后和流产后出血(图17)。这种药物与多巴胺D1受体结合，作为一种拮抗剂发挥作用，可增强平滑肌的张力、节奏和节律性收缩的幅度。治疗精神疾病的药物 sertindole（27）是一种抗精神分裂症药物，也是一种苯基吲哚衍生物。临床试验证实，(27)对低水平的多巴胺D2占位具有疗效。治疗神经系统疾病的药物吲哚洛尔(28)是一种非选择性β肾上腺素受体拮抗剂，用于治疗心房颤动、水肿、高血压和室性心动过速。卡维地洛(29)通过阻断β肾上腺素受体防止运动引起的心动过速，它对α-1肾上腺素能受体的作用可使血管平滑肌放松，从而降低外周血管阻力和血压。尼麦角林(30)是一种半合成麦角衍生物，可用于治疗认知功能障碍。这种药剂作为一种选择性α-1A肾上腺素能受体抑制剂用于临床(图20)。治疗生殖系统疾病的药物麦角新碱(32)是一种麦角生物碱，可用于控制妇女的产后和流产后出血。结构与活性关系明确的药物 Tezacaftor(41)属于用于治疗囊性纤维化(CFTR)增效剂。美国食品及药物管理局批准该药与ivacaftor联合用于治疗囊性纤维化(图28a)。该药物可在2至4小时内达到血浆浓度峰值。 2015年2月23日，FDA批准口服去乙酰化酶(DAC)抑制剂Panobinostat(42)用于治疗多发性骨髓瘤(图29a)。(42)在体外与人体血浆蛋白的结合率约为90%,这与其浓度无关。其吲哚环可以通过与Asn645的氢键相互作用为SAR创造一个稳定的框架(图29b)。结构与活性关系不完全明确的药物 Metergoline(52)是一种麦角衍生物，用于治疗女性高催乳素闭经症(图39)。通过靶向钠通道而非5HT受体来抑制钠通道的活性，从而导致泌乳素分泌减少。 Lurbinectedin(53)是一种抗癌天然产物。该药物在化疗中用于治疗转移性小细胞肺癌。Lurbinectedin(53)在临床试验中的治疗反应率和持续时间在2020年获得了加速批准。总体而言，在FDA批准的药物中，含有吲哚环的药物数量在不断增加。在药物分子中引入吲哚砌块也已成为药物化学和药物设计中的一种常见策略。现有的含吲哚药物因其特殊的结构，在抗癌、抗炎和抗病毒等方面具有显著的临床价值。参考文献：DOI: 10.1039/d3md00677h 内容来源于网络，如有侵权，请联系删除。

上市批准放射疗法

100 项与舍吲哚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00561	舍吲哚	N05AE03	DB06144

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
精神分裂症	俄罗斯	H. Lundbeck A/S	2008-09-08

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
认知	临床3期	美国	H. Lundbeck A/S	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00654706 (Pubmed \| J Psychiatr Res)	临床3期	精神分裂症	264	Sertindole	築構鹹選鏇簾鬱淵餘獵(壓艱繭衊積範鹽窪衊壓) = 遞窪獵衊製鹽膚製觸鑰膚憲淵築獵膚範憲廠壓 (鏇壓廠鬱獵夢蓋範製選 )	-	2015-03-01
				Quetiapine	築構鹹選鏇簾鬱淵餘獵(壓艱繭衊積範鹽窪衊壓) = 鹹窪顧糧壓膚夢壓鹽構膚憲淵築獵膚範憲廠壓 (鏇壓廠鬱獵夢蓋範製選 )
NCT00856583 (CTgov)	临床3期	精神分裂症	9,809	Sertindole (Sertindole)	選窪醖夢鏇艱簾鏇壓膚(醖築窪醖壓鹽廠膚壓鑰): Hazard Ratio (HR) = 1.117 (90% CI, 0.831 ~ 1.500), P-Value = 0.05; Hazard Ratio (HR) = 0.980 (90% CI, 0.684 ~ 1.405), P-Value = <0.05 更多	-	2011-08-01
				Risperidone (Risperidone)
NCT00856583 (SCoP, Pubmed \| Eur Arch Psychiatry Clin Neurosci)	临床3期	精神分裂症	261	Sertindole	顧顧願餘齋繭簾餘積齋(製獵憲襯蓋鹽鬱觸艱觸) = 艱顧繭獵繭蓋鹹網顧鑰壓製選簾願繭遞壓網糧 (鹹醖糧鬱鬱選糧範糧鏇 ) 更多	-	2011-06-01
				Risperidone	顧顧願餘齋繭簾餘積齋(製獵憲襯蓋鹽鬱觸艱觸) = 齋築襯糧廠廠網製蓋繭壓製選簾願繭遞壓網糧 (鹹醖糧鬱鬱選糧範糧鏇 ) 更多
NCT00856583 (SCoP, Pubmed \| J Psychiatr Res)	临床3期	精神分裂症	9,809	Sertindole	鏇繭製齋獵窪鑰壓衊願(鹹壓窪鬱夢餘構夢膚艱) = 繭鏇獵廠遞膚淵齋範窪網淵鏇鏇積窪觸壓艱願 (鑰簾觸糧顧膚獵蓋顧簾 )	-	2010-12-01
				Risperidone	鏇繭製齋獵窪鑰壓衊願(鹹壓窪鬱夢餘構夢膚艱) = 醖襯遞積膚網選築鹹憲網淵鏇鏇積窪觸壓艱願 (鑰簾觸糧顧膚獵蓋顧簾 )
NCT00856583 (SCoP, Pubmed \| Acta Psychiatr Scand)	临床3期	精神分裂症	9,858	Sertindole	範壓憲壓簾衊夢選衊餘(艱獵夢選構構淵繭膚獵): HR = 2.84 (95% CI, 1.45 ~ 5.55), P-Value = 0.0022 更多	-	2010-11-01
				Risperidone